Vivos Inc (RDGL)

[Kooka_Duke]

To Come On a Board After Being Dormant For Years And Announce You Doubled Out & Recommend Others To Do The Same, And To Spew Out Comments About The O/S..,Debt & Financing..,Doesn't Sound Like a Person That Has a Position Here On ADMD!!

Here's What I Recommend You Do Before Sharing Your Unwanted Thoughts Here On ADMD!

#1. Do Some DD

ADMD SS:, In Case You Didn't Know, The O/S Isn't As High You Think It Is.. As Of 03/26/15, And Validated By The T/A......

A/S 2B
O/S 1.8B
Float 930M...>>>>> 1.1B Minus 70M Restricted = 930M

So From The SS: The Float Is Owned By The LONGS & Is Being Locked Down Tight!<<<<<<......By The Way The Accum/Dist Level Is Well Over 1.3B, And IF"" There Was Dilution From 3/26/15 Till This Week When The News Dropped About ""NO DILUTION"" It Was Gobbled Up By More Longs!!!!!

#2. Financing....The News On Thursday Put To Rest Questions About Financing.., & Debt:

KENNEWICK, WA -- April 23, 2015 -- InvestorsHub NewsWire -- Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications, today provided information on completion of the initial steps of the Company’s capital restructuring plan.

AMIC is pleased to announce that it has reached an agreement with its primary lender, Carlton Cadwell, and his affiliated entities to convert $5 million of long term debt into a newly designated series of equity based convertible preferred stock. In addition, several other lenders have agreed to these debt conversion terms.

The Series A Convertible Preferred Stock will be convertible at a fixed price of $0.015 per share and will be treated as equity on the company’s balance sheet. The remaining debt held by the Cadwell family and associated entities totaling approximately $1 million will be exchanged for a new non-convertible 6% note that matures on December 31, 2017.

These debt conversion agreements are subject to final documentation which is expected before the end of this quarter, and all will be deemed to be affiliates with appropriate lock-up agreements.

Under terms of the newly created Series A, upon completion of an up listing transaction to a national exchange, all shares of Series A stock will convert into common stock.

In addition to the elimination and exchange of the Cadwell debt referenced above, the company has also successfully eliminated approximately $500,000 of seasoned trade payables, without additional dilution of existing shareholders. It is anticipated that these items will be reflected in the company’s 2nd quarter 10-Q filing.

......So Yes There Was Some Dilution Going On Here In The Last Month Or So, However Like I Mentioned Before These Shares Where Gobbled Up Big Time As Indicated By The Accum/Dist Level Being Well Over 1.3B!!......Remember Players There's Only 200Milly More Left In The Kitty (A/S 2B.., O/S 1.8B) So We Could Very Well Be Maxed OUT!!!!....Good News Is There Will Be No More Additional DILUTION""

CEO James C. Katzaroff stated “We are very grateful for the continued support and commitment of the Cadwell family and associated entities. This important step, as the company moves to normalize its capital structure and balance sheet, is in anticipation of capitalizing the company to pursue commercial opportunities for our Y-90 product line.”

The Company’s primary focus continues to be obtaining regulatory clearance by the FDA of the Y-90 RadioGel(TM) device. The Company is awaiting feedback from the FDA on the de novo requesting regulatory clearance to market the Y-90 RadioGel(TM) device. Previously, the FDA found the same device under Section 510(k) of the Act not substantially equivalent, and concluded that the device is classified by statute as a Class III medical device, unless the device is reclassified. By filing the de novo, the Company is seeking reclassification of the product to Class II.

If the de novo is granted, the device may be immediately marketed in the United States and the company will pursue funding toward the US commercialization effort. If the de novo is declined, the Company may elect to seek additional funding to secure approval for the device as a Class III medical device in the US. Alternatively, and based on the feedback from our existing and potential investors, the Company may seek funding to pursue marketing approval for the Y-90 RadioGel™ device in Europe, Canada or Asia which could present a faster path toward commercialization.

CEO James C. Katzaroff concluded: “AMIC remains focused on the commercialization of its Y-90 brachytherapy products that have been developed to offer new solutions for cancer treatment that improve on the safety, cost and efficacy of existing treatments. A cleaner, healthier balance sheet and simplified capital structure is an important element in the Company’s financing plan in support of the commercialization goals. Today’s announcement on debt conversion is an important initial step in executing our strategic plan.”

........This Little Tid Bit Is Huge Players.....Mr.Katzaroff Is Letting Us Into His Mind Of Getting This Product Financed To Bring It To Market & The Primary Lender Cadwell Is So Generous That He Agreed With The New Terms Of Debt Restructuring.....Hmmmmm I Wonder Why He's Willing To Do That????? Is It Because He Knows In His Mind That The Y-90 RadioGel(TM) Is Going To Be FDA Approved? Hell Yea!!!! Why Else Would He Put Up So Much Capital Well Over 5Milly!!!!